Ipsen S.A. is a global biopharmaceutical company that develops and commercializes specialty medicines to address high unmet medical needs. The company's business is structured around three core therapeutic areas: oncology, neuroscience, and rare diseases. Its flagship oncology portfolio includes Somatuline for neuroendocrine tumors, Cabometyx for renal cell carcinoma, and Onivyde for metastatic pancreatic cancer. In neuroscience, the company's key product is Dysport, a botulinum toxin used for both therapeutic and aesthetic indications. Ipsen maintains a robust research and development pipeline, supported by strategic acquisitions and partnerships, with R&D centers located in France, the UK, and the US. The company distributes its products globally, with a direct commercial presence in over 30 countries and products registered in more than 100 countries.
